Drug Trial Radar · NCT05491317
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Mar 8, 2023
Primary completion
Aug 11, 2025
Study completion Aug 11, 2025
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Aug 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors.
Conditions
- Non-CNS Tumor
Interventions
GEN1042Biological
Intravenous
PembrolizumabDrug
Intravenous
RadiotherapyRadiation
Radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: 21 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.